|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-4-21
|
|
pubmed:abstractText |
Non-muscle invasive bladder cancer (BC) is a highly recurrent disease, with the first recurrences arising shortly after transurethral resection of the bladder (TURB). Topical administration of interleukin-2 (IL-2) has been shown as an effective adjuvant therapy for BC; however, predictive biomarkers that may identify suitable subgroups of patients are lacking. In this pilot study we sought to determine the prognostic value of epigenetic and genetic inactivation of tumour suppressor genes (TSGs) among BC patients treated with IL-2.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Apoptosis Regulatory Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium-Calmodulin-Dependent...,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/RASSF1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Retinoic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/death-associated protein kinase,
http://linkedlifedata.com/resource/pubmed/chemical/retinoic acid receptor beta
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1432-1335
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
136
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
847-54
|
|
pubmed:meshHeading |
pubmed-meshheading:19924441-Adult,
pubmed-meshheading:19924441-Aged,
pubmed-meshheading:19924441-Antineoplastic Agents,
pubmed-meshheading:19924441-Apoptosis Regulatory Proteins,
pubmed-meshheading:19924441-Calcium-Calmodulin-Dependent Protein Kinases,
pubmed-meshheading:19924441-Cystoscopy,
pubmed-meshheading:19924441-DNA Methylation,
pubmed-meshheading:19924441-Female,
pubmed-meshheading:19924441-Genes, Tumor Suppressor,
pubmed-meshheading:19924441-Genes, p16,
pubmed-meshheading:19924441-Genes, p53,
pubmed-meshheading:19924441-Humans,
pubmed-meshheading:19924441-Interleukin-2,
pubmed-meshheading:19924441-Male,
pubmed-meshheading:19924441-Middle Aged,
pubmed-meshheading:19924441-Mutation,
pubmed-meshheading:19924441-Pilot Projects,
pubmed-meshheading:19924441-Polymerase Chain Reaction,
pubmed-meshheading:19924441-Polymorphism, Single-Stranded Conformational,
pubmed-meshheading:19924441-Promoter Regions, Genetic,
pubmed-meshheading:19924441-Prospective Studies,
pubmed-meshheading:19924441-Receptors, Retinoic Acid,
pubmed-meshheading:19924441-Treatment Outcome,
pubmed-meshheading:19924441-Tumor Suppressor Proteins,
pubmed-meshheading:19924441-Urinary Bladder Neoplasms
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study.
|
|
pubmed:affiliation |
Faculty of Natural Sciences, Vilnius University, Ciurlionio 21, 3101 Vilnius, Lithuania. sonata.jarmalaite@gf.vu.lt
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
